STOCK TITAN

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

NanoViricides (NYSE: NNVC), a clinical-stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. Company President & Executive Chairman Anil R. Diwan will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.

Loading...
Loading translation...
Argus Session date unavailable
-3.65% session move Open Argus
Details

News Market Reaction – NNVC

The recorded move for NNVC in the trading session of this news was -3.65%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.

Anil R. Diwan, President & Executive Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).

To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.

About NanoViricides

The Company has developed a novel broad-spectrum antiviral drug, NV-387, that can treat many unrelated viral infections and could be as revolutionary as the development of penicillin to treat many bacterial infections. NV-387, has completed Phase I human clinical trial successfully. The Company is preparing an application for a Phase II human efficacy clinical trial of NV-387 for the treatment of MPox in African region. Additional clinical trials for RSV, Influenza, COVID and other respiratory infections are planned. NV-387 is expected to be active for treatment of Measles virus infection as well. Additionally, the Company has developed NV-HHV-1, a drug for treatment of almost all herpesvirus infections, and NV-HIV-1 for treatment of HIV/AIDS. The Company's technology uniquely enables drugs that the virus cannot escape from, despite constant changes in the virus that have stymied traditional antibodies vaccines and small therapeutics approaches. The overall market size for the above three products alone is in the range of $20 to $30 Billions.

About D. Boral Capital

D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.

D. Boral Capital is a leader on Wall Street, having aggregated over $25 billion in capital across approximately 350 transactions through various product types.

For further information:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

www.nanoviricides.com

Source NanoViricides, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250560

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of NanoViricides (NNVC) participating in the D. Boral Capital Conference 2025?

NanoViricides will participate to meet with interested parties in one-on-one meetings, providing an opportunity to discuss their clinical-stage antiviral development programs and technology.

When and where is NanoViricides (NNVC) presenting at the D. Boral Capital Conference?

The conference is taking place on May 14, 2025, at The Plaza Hotel in New York City, with one-on-one meetings scheduled from 9:00 A.M. to 3:00 P.M. (ET).

Who will represent NanoViricides (NNVC) at the D. Boral Capital Conference 2025?

Anil R. Diwan, President & Executive Chairman of NanoViricides, will be hosting the one-on-one meetings at the conference.

How can investors schedule meetings with NanoViricides (NNVC) management at the conference?

Interested parties can schedule one-on-one meetings by contacting John Perez at jperez@dboralcapital.com.

Keep reading